Breast Cancer induced Bone Disease (CTIBL)

Breast cancer remains the most commonly diagnosed cancer worldwide and the leading cause of cancer mortality in women, making it a significant global public health concern. According to the World Health Organization (WHO), an estimated 2.3 million women were diagnosed with breast cancer in 2022, resulting in approximately 670,000 deaths.

Aromatase inhibitors are a cornerstone of adjuvant treatment for hormone-responsive breast cancer, significantly reducing the risk of recurrence. However, they also accelerate bone resorption, leading to a higher incidence of osteoporosis and fractures.

In this lecture, Professor Peyman Hadji discusses the latest recommendations for the assessment and management of aromatase inhibitor-associated bone loss (AIBL), based on the most recent joint statement from the different leading medical societies. The lecture highlights how new evidence has been integrated with existing guidelines to provide evidence-based recommendations for fracture risk assessment and the use of bone-directed therapies in clinical practice.
 

Key Learning Objectives of this lecture include:

• Understanding the pathophysiology and clinical impact of aromatase inhibitor-associated bone loss (AIBL) in women receiving adjuvant endocrine therapy for hormone-sensitive breast cancer.
• Reviewing current evidence-based guidelines for assessing fracture risk and monitoring bone health in patients receiving aromatase inhibitor therapy.
• Examining new insights on how bone-protective therapies may influence breast cancer outcomes

All proceeds from the IOF Academy directly contribute to IOF’s global projects and programmes dedicated to better bone health and patient care.

Uploaded in november 2025